22.26
+2.96%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Replimune Group
From its filings with the US Securities and Exchange Commission
Replimune Group is based in Woburn, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker REPL. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 March 2026, it reported a net loss of $313.9m. At that date it held total assets of $332.4m and shareholders' equity of $166.2m.
We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through our novel oncolytic immunotherapies. Our proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer.
Oncolytic immunotherapy is an emerging drug class. Oncolytic immunotherapy exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. Our product candidates incorporate multiple mechanisms into a practical “off-the-shelf” approach that is intended to maximize the immune response against a patient’s cancer and to offer significant advantages over other approaches to inducing anti-tumor immunity. We believe that the bundling of multiple approaches for the treatment of cancer into single therapies will increase clinical efficacy and simplify the development path of our product candidates, while also improving patient outcomes.
Our proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.
Quoted from its 10-K, filed 29 Jun 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Jul 2018
- Employees
- 465
- Website
- replimune.com ↗
- Head office
- 500 UNICORN PARK, WOBURN, MA, 01801
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Philip Astley-SparkeExecutive Chairman of the Board, since 2015$6.0m
- Dr. Sushil PatelChief Executive Officer, Director, since 2021$3.7m
- Ms. Emily HillChief Financial Officer$1.6m
- Mr. Christopher SarchiChief Commercial Officer
- Dr. Konstantinos XynosChief Medical Officer$1.6m
- Mr. Dieter WeinandLead Independent Director$264,049
- Mr. Madhavan BalachandranDirector$486,706
- Dr. Kapil DhingraIndependent Director$235,161
- Mr. Michael GollerIndependent Director$543,132
- Ms. Christy OligerIndependent Director$234,258
- Ms. Veleka Peeples-DyerIndependent Director$227,661
- Mr. Paolo PucciIndependent Director$227,419
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 36
- Environment
- 34
- Social
- 49
- Governance
- 25
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Replimune Group Inc has several strengths that give it a competitive edge in the market. These include:
Weaknesses
- Despite its strengths, Replimune Group Inc also faces certain weaknesses that may hinder its growth and profitability. These weaknesses include:
Opportunities
- Replimune Group Inc can capitalize on several opportunities in the market to enhance its growth prospects. These opportunities include:
Threats
- Replimune Group Inc faces various threats that could impact its performance and market position. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.